Loading…
ADMA Biologics, Inc. is projected to rise to $9.08 by 2027, a +15% move from its current price of $7.92. ADMA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $7.70 | $7.92 | $8.16 | +0.05% |
| May 30 | $7.61 | $7.93 | $8.26 | +0.10% |
| May 31 | $7.54 | $7.93 | $8.34 | +0.15% |
| Jun 1 | $7.49 | $7.94 | $8.41 | +0.19% |
| Jun 2 | $7.44 | $7.94 | $8.47 | +0.24% |
| Jun 3 | $7.39 | $7.94 | $8.53 | +0.29% |
| Jun 4 | $7.36 | $7.95 | $8.59 | +0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.36 | $7.95 | $8.59 | +0.34% |
| Week 2 | $7.15 | $7.97 | $8.89 | +0.68% |
| Week 3 | $7.00 | $8.00 | $9.15 | +1.02% |
| Week 4 | $6.88 | $8.03 | $9.37 | +1.36% |
| Week 5 | $6.78 | $8.06 | $9.57 | +1.71% |
| Week 6 | $6.69 | $8.08 | $9.77 | +2.05% |
| Week 7 | $6.61 | $8.11 | $9.95 | +2.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin.
In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc.
was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
The asset's current price is $8.24 and it has a market cap of $1.91B, with a market rank of 2034. The current price and market position frame the stock among healthcare names with a sizable market capitalization. Forecasts place the 2026 average price at $8.24 with an ROI of 0 and a neutral sentiment, suggesting an even start to the multi-year outlook.
A major floor 28.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.5% away) — a key level to hold.
The nearest ceiling, 42.2% above — a clean break opens room to run.
A major ceiling 122.1% above — clearing it would confirm fresh momentum.
Key ADMA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ADMA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.27 | Sell | $8.19 | Sell |
| MA 10 | $8.36 | Sell | $8.40 | Sell |
| MA 20 | $8.93 | Sell | $8.89 | Sell |
| MA 50 | $10.11 | Sell | $10.42 | Sell |
| MA 100 | $13.38 | Sell | $12.37 | Sell |
| MA 200 | $15.05 | Sell | $14.24 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 29.82 | Buy |
| Stoch RSI (14) | 50.89 | Neutral |
| CCI (20) | -79.53 | Neutral |
| Williams %R (14) | -94.67 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -3.06 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 5.33 | Buy |
| TRIX (15) | -0.98 | Sell |
| Awesome (5,34) | -1.39 | Sell |
| Ultimate (7,14,28) | 30.21 | Neutral |
| Momentum (10) | -0.49 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 8.10 | Sell |
| ADX (14) | 30.96 | Sell |
| ATR (14) | 0.25 | Info |
The 30-day range is $6.75 to $10.07, with the current price of $8.24 sitting within that window. RSI14 is 30 and the overall sentiment is NEUTRAL. The moving averages show SMA50 at $10.41 and SMA200 at $15.13, with nearby support at $7.88 and resistance at $11.26.
These levels help define potential entry and exit points in the near term. Annualized volatility is 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.88 | $7.92 | $11.17 | 0% | Neutral | |
| $7.16 | $9.08 | $12.24 | +15% | Neutral | |
| $7.06 | $9.23 | $12.93 | +17% | Neutral | |
| $7.35 | $9.85 | $14.20 | +24% | Bullish | |
| $6.80 | $9.31 | $13.77 | +18% | Neutral | |
| $6.90 | $9.63 | $14.57 | +22% | Bullish | |
| $8.08 | $11.50 | $17.73 | +45% | Bullish | |
| $8.76 | $12.68 | $19.91 | +60% | Bullish | |
| $9.49 | $13.97 | $22.30 | +76% | Bullish | |
| $9.30 | $13.91 | $22.55 | +76% | Bullish | |
| $12.49 | $20.11 | $34.76 | +154% | Bullish | |
| $16.78 | $30.66 | $58.19 | +287% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $7.88 | $7.92 | $9.29 | +0.00% |
| June 2026 | $6.71 | $7.90 | $9.52 | -0.28% |
| July 2026 | $6.97 | $8.28 | $10.12 | +4.81% |
| August 2026 | $7.17 | $8.57 | $10.60 | +3.59% |
| September 2026 | $7.09 | $8.52 | $10.63 | -0.63% |
| October 2026 | $7.12 | $8.61 | $10.83 | +1.08% |
| November 2026 | $7.30 | $8.87 | $11.23 | +2.96% |
| December 2026 | $7.18 | $8.76 | $11.17 | -1.21% |
Click any year to see its month-by-month ADMA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ADMA could reach as high as $11.17, with a base case around $7.92 and support toward $7.88 — roughly 0% from $7.92. Price action looks broadly range-bound.
Expect ADMA to range from $7.16 to $12.24 through 2027. The $9.08 average target implies a +15% move from current prices. That is up +15% on the projected 2026 average. A consolidation phase looks the most probable path here.
The ADMA price prediction for 2028 points to an average of $9.23 (low $7.06, high $12.93) — a potential gain of +17% on today's $7.92. Price action looks broadly range-bound.
In 2029, ADMA is projected to trade between $7.35 and $14.20, averaging $9.85 — a potential gain of +24% from today's $7.92. That is up +7% on the projected 2028 average. Buyers look set to stay in control over this stretch.
ADMA Biologics, Inc.'s 2030 outlook centres on $9.31, within a $6.80 to $13.77 range. That is -5% versus the projected 2029 average. That marks a +18% change versus current levels. Price action looks broadly range-bound.
By 2031, ADMA could reach as high as $14.57, with a base case around $9.63 and support toward $6.90 — roughly +22% from $7.92. Buyers look set to stay in control over this stretch.
Expect ADMA to range from $8.08 to $17.73 through 2032. The $11.50 average target implies a +45% move from current prices. That is up +19% on the projected 2031 average. Momentum favours further upside here.
The ADMA price prediction for 2033 points to an average of $12.68 (low $8.76, high $19.91) — a potential gain of +60% on today's $7.92. Buyers look set to stay in control over this stretch.
In 2034, ADMA is projected to trade between $9.49 and $22.30, averaging $13.97 — a potential gain of +76% from today's $7.92. That is up +10% on the projected 2033 average. Momentum favours further upside here.
ADMA Biologics, Inc.'s 2035 outlook centres on $13.91, within a $9.30 to $22.55 range. That is 0% versus the projected 2034 average. That marks a +76% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ADMA could reach as high as $34.76, with a base case around $20.11 and support toward $12.49 — roughly +154% from $7.92. Momentum favours further upside here.
Expect ADMA to range from $16.78 to $58.19 through 2050. The $30.66 average target implies a +287% move from current prices. That is up +52% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ADMA today (≈ 126.262626 ADMA) could be worth
$3,871.16
+$2,871.16 (+287%) by 2050 · US Dollar
Based on the average projected ADMA price of $30.66 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ADMAwould be worth at today's price.
$1,000 invested in ADMA on May 27, 2025 (≈ 50.276522 ADMA) would be worth
$398.19
-$601.81 (-60.2%) today · 0.40× · US Dollar
Based on a ADMA entry price of $19.89 vs. today's $7.92.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.56 | $925.23 | -7.5% |
| 1 month ago | $10.93 | $724.61 | -27.5% |
| 3 months ago | $15.18 | $521.74 | -47.8% |
| 6 months ago | $19.18 | $412.93 | -58.7% |
| 1 year ago | $19.89 | $398.19 | -60.2% |
| All time (5.0y) ago | $1.75 | $4,525.71 | +352.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ADMA forecast.
Our base-case forecast reaches $16.00 around 2040.
Implied market cap at $16.00: $3.71B
In the 2026 forecast, the average price is $8.24 with a min of $7.88 and a max of $11.63, and the roiPct is 0 with NEUTRAL sentiment. The years that follow project a gradual rise in average prices and include several years labeled BULLISH, such as 2029 (avg $10.26, ROI 24.5) and 2031 (avg $10.15, ROI 23.2). By 2032 the average price is forecast at $12.18 (ROI 47.8) and 2033 at $13.53 (ROI 64.2), with 2034 at $14.85 (ROI 80.2) and 2035 at $14.68 (ROI 78.2), all with BULLISH sentiment in those years.
Tap a question to reveal the answer.
In 2030, the average price is $9.76, the min is $7.07, the max is $14.57, with an ROI of 18.5% and NEUTRAL sentiment.
The forecast shows several years with BULLISH sentiment and rising ROIs later in the horizon, including 2029 (ROI 24.5%), 2032 (ROI 47.8%), 2033 (ROI 64.2%), 2040 (ROI 163.1%), and 2050 (ROI 293.8%), suggesting upside potential in multiple years.
Yes. The max forecasts reach $23.97 in 2034 and $24.07 in 2035.
Current price is $8.24 and market capitalization is $1.91B.
The 2026 forecast shows an average price of $8.24 with ROI 0 and NEUTRAL sentiment, and 2027–2029 show increasing averages toward $10.26 by 2029, with 2029 labeled BULLISH and ROI 24.5%.
ADMA Biologics, Inc. Community Discussion
0Share your ADMA Biologics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.